Anti- CD51 (Integrin Subunit Alpha V) [NKIM9] monoclonal antibody
Invented by Prof Arnoud Sonnenberg from Netherlands Cancer Institute
Invented at Netherlands Cancer Institute
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 154749 |
| Applications | FACS IHC IF IP |
| Antigen/Gene or Protein Targets | CD51 |
| Synonyms | ITGAV; Vitronectin Receptor |
| Reactivity | Human |
| Relevance | ITGAV encodes integrin alpha chain V. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. Alpha V undergoes post-translational cleavage to yield disulfide-linked heavy and light chains, that combine with multiple integrin beta chains to form different integrins. Among the known associating beta chains (beta chains 1,3,5,6, and 8; 'ITGB1', 'ITGB3', 'ITGB5', 'ITGB6', and 'ITGB8'), each can interact with extracellular matrix ligands; the alpha V beta 3 integrin, perhaps the most studied of these, is referred to as the Vitronectin receptor (VNR). In addition to adhesion, many integrins are known to facilitate signal transduction |
| Host | Mouse |
| Immunogen | Cultured melanoma cells derived from a human melanoma metastasis. |
| Subclass | IgG2a |
| Molecular Weight (kDa) | 116 |
| Myeloma Used | Sp2/0-Ag14 |
| Recommended Growing Conditions | IMDM + 4% FBS ulta low IgG, 37 ⁰C 5% CO2 |
| Strain | Balb/c |
| Notes |
Fusion partners: SP2/0 mouse myeloma cells with spleen cells from a BALB/c mouse immunized with cultured melanoma cells derived from a human melanoma metastasis The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors |
| Research Area | Adhesion, Immunology |
